<div><div></div><div><span><p><span>Bio-Techne entered into an Agreement and Plan of Merger with Merck, Darmstadt, Germany, under which Merck will acquire Bio-Techne for $73.00 per share in cash. Following the merger, Bio-Techne will become a wholly owned subsidiary of Merck, subject to shareholder approval and customary regulatory clearances. The agreement includes customary terms, closing conditions, and termination fee provisions for both parties.</span></p><p><strong><span>Agreement details:</span></strong></p><ul><li><strong><span>Agreement type</span></strong><span>: Agreement and Plan of Merger (all-cash acquisition)</span></li><li><strong><span>Counterparty</span></strong><span>: Merck, Darmstadt, Germany</span></li><li><strong><span>Signed / Effective</span></strong><span>: Jun 25 2026 / N/A</span></li><li><strong><span>Reason</span></strong><span>: Provide immediate cash value and strategic scale under Merck</span></li></ul><p><span>Original SEC Filing: </span>BIO-TECHNE Corp [ TECH ] - 8-K - Jun. 25, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

TECH

<p>Bio-Techne has entered into an agreement to be acquired by Merck, Darmstadt, Germany, in an all-cash merger valued at $73.00 per share. Upon completion, subject to shareholder approval and regulatory clearances, Bio-Techne will become a wholly owned subsidiary of Merck. The deal aims to provide immediate cash value and strategic scale.</p>

Bio-Techne to Be Acquired by Merck for $73 Per Share in All-Cash Merger